BioCurity

BioCurity develops a platform for biotechnology called 'Sentry' for treating radiation-related xerostomia and radiation dermatitis.

Radiation exposure is an increasing concern in medical, military and homeland security scenarios. BioCurity has developed both injectable and topical cream radioprotectant products, called RadGuard. Both eliminate ionized free radicals that cause cellular damage resulting from radiation. The cream is used to prevent radiation exposure to skin before cancer radiation treatments. It can also be used as a first-responder “stop gap” treatment for post-exposure events such as military “dirty bombs” and civilian nuclear threats. The injectable product supplements the cream for radiation exposure scenarios that require protection or post-exposure mitigation for organs and other deep tissues. BioCurity is pursuing FDA approval for both RadGuard products, which have been funded to date by funding from the National Institutes of Health.